{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:20:10Z","timestamp":1791231610348,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Renal cell carcinoma (RCC) associated with Xp11.2 translocation\/TFE3 gene fusions is a rare subtype of renal tumor. This entity predominantly occurs in juveniles, but rarely in adults. Xp11.2 translocation RCC (tRCC) patients with lymph node or organ metastasis are associated with poor prognosis, and the strategy remains controversial. Herein, we presented our experience with the diagnosis and treatment of an adult case of Xp11.2 tRCC. In our clinical practice, a 32-year-old male manifested fever and right flank paroxysmal blunt pain, and computed tomography showed an inhomogeneous mass, 6\u00a0cm in diameter, in the right kidney. Then right partial nephrectomy (PN) and renal hilar lymph node dissection by laparoscopic surgery were performed. Pathology revealed that the tumor cells were positive for TFE3 immunohistologically and positive for TFE3 break-apart fluorescence <jats:italic>in situ<\/jats:italic> hybridization assay. A splice site mutation c.1544-1G&amp;gt;T of protein tyrosine phosphatase receptor delta (<jats:italic>PTPRD<\/jats:italic>) was detected by next-generation sequencing and weak PTPRD expression was confirmed in tumor tissues compared to tumor periphery. This patient was diagnosed with stage III RCC and received immune checkpoint inhibitor (camrelizumab) in combination with tyrosine kinase inhibitor (axitinib) treatment for 1\u00a0year. He achieved a clinical complete response with no sign of recurrence or metastasis. <jats:italic>PTPRD<\/jats:italic> mutation might be a favorable indicator for Xp11.2 tRCC patients managed by PN and followed by the adjuvant therapy of immune checkpoint inhibitor and tyrosine kinase inhibitor.<\/jats:p>","DOI":"10.3389\/fphar.2022.927299","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T07:33:51Z","timestamp":1660203231000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation\/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Juping","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1043\/2008-0391-RSR.1","article-title":"Xp11.2 translocation renal cell carcinoma","volume":"134","author":"Armah","year":"2010","journal-title":"Arch. Pathol. Lab. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s13046-019-1469-4","article-title":"PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin","volume":"38","author":"Bae","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s40425-018-0482-z","article-title":"Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders","volume":"6","author":"Boil\u00e8ve","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1097\/01.pas.0000131558.32412.40","article-title":"Morphologic and molecular characterization of renal cell carcinoma in children and young adults","volume":"28","author":"Bruder","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/cancers11081110","article-title":"MiT family translocation renal cell carcinoma: From the early descriptions to the current knowledge","volume":"11","author":"Cali\u00f2","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1002\/cncr.25512","article-title":"Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma","volume":"116","author":"Choueiri","year":"2010","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cell.2019.10.007","article-title":"Integrated proteogenomic characterization of clear cell renal cell carcinoma","volume":"179","author":"Clark","year":"2019","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1073\/pnas.0408593102","article-title":"A survey of homozygous deletions in human cancer genomes","volume":"102","author":"Cox","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.2217\/fon.15.177","article-title":"Renal cell carcinoma associated with Xp11.2 translocation\/TFE3 gene fusions: Clinical experience and literature review","volume":"11","author":"He","year":"2015","journal-title":"Future Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/iju.13007","article-title":"Clinicopathological characteristics of Xp11.2 translocation renal cell carcinoma in adolescents and adults: Diagnosis using immunostaining of transcription factor E3 and fluorescence in situ hybridization analysis","volume":"23","author":"Hirobe","year":"2016","journal-title":"Int. J. Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1309\/AJCPQ6LLFMC4OXGC","article-title":"Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: Incidence, characteristics, and prognosis","volume":"137","author":"Klatte","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2478\/raon-2013-0077","article-title":"Xp 11.2 translocation renal carcinoma in young adults; recently classified distinct subtype","volume":"48","author":"Kmetec","year":"2014","journal-title":"Radiol. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1002\/cncr.26028","article-title":"D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta","volume":"117","author":"Li","year":"2011","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0166897","DOI":"10.1371\/journal.pone.0166897","article-title":"Renal cell carcinoma associated with Xp11.2 translocation\/TFE3 gene fusions: Clinical features, treatments, and prognosis","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s13691-020-00430-6","article-title":"Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: Case report and literature review","volume":"9","author":"Masago","year":"2020","journal-title":"Int. Cancer Conf. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, anti-tumor activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: A dose-escalation, phase 1 study","volume":"119","author":"Mo","year":"2018","journal-title":"Br. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8149","DOI":"10.1073\/pnas.1401952111","article-title":"Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis","volume":"111","author":"Ortiz","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/1066896910375565","article-title":"Xp11.2 translocation renal cell carcinomas have a poorer prognosis than non-xp11.2 translocation carcinomas in children and young adults: A meta-analysis","volume":"18","author":"Qiu Rao","year":"2010","journal-title":"Int. J. Surg. Pathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"21677","DOI":"10.1038\/srep21677","article-title":"Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: Clinicopathological data from ethnic Chinese population","volume":"6","author":"Qu","year":"2016","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1158\/1078-0432.CCR-21-1698","article-title":"Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: Data from an open-label, multicenter phase II basket study","volume":"27","author":"Qu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.1133427","article-title":"The consensus coding sequences of human breast and colorectal cancers","volume":"314","author":"Sj\u00f6blom","year":"2006","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"10300","DOI":"10.1158\/0008-5472.CAN-08-3272","article-title":"Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma","volume":"68","author":"Solomon","year":"2008","journal-title":"Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/PAS.0b013e31824dd972","article-title":"TFE3 rearrangements in adult renal cell carcinoma: Clinical and pathologic features with outcome in a large series of consecutively treated patients","volume":"36","author":"Sukov","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-20-3788","article-title":"Integrated molecular characterization of fumarate hydratase-deficient renal cell carcinoma","volume":"27","author":"Sun","year":"","journal-title":"Clin. Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12916-021-02075-5","article-title":"Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC","volume":"19","author":"Sun","year":"","journal-title":"BMC Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"9435","DOI":"10.1073\/pnas.0900571106","article-title":"The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers","volume":"106","author":"Veeriah","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"650122","DOI":"10.3389\/fonc.2021.650122","article-title":"Association of PTPRD\/PTPRT mutation with better clinical outcomes in NSCLC patients treated with immune checkpoint blockades","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nature06358","article-title":"Characterizing the cancer genome in lung adenocarcinoma","volume":"450","author":"Weir","year":"2007","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1038\/onc.2014.326","article-title":"Genetic alterations of protein tyrosine phosphatases in human cancers","volume":"34","author":"Zhao","year":"2015","journal-title":"Oncogene"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.927299\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T07:33:53Z","timestamp":1660203233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.927299\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":32,"alternative-id":["10.3389\/fphar.2022.927299"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.927299","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"article-number":"927299"}}